Study of High Performance Liquid Chromatography and Turbidimetric Inhibition Immunoassay for HbA1c Analysis in Diabetic Patients with Variant Hemoglobin

Sultana GS\textsuperscript{a}, Khan NZ\textsuperscript{b}, Khuda Zc, Sultana TA\textsuperscript{d}, Dipta TF\textsuperscript{e}, Muttalib MA\textsuperscript{f}, Choudhury S\textsuperscript{g}

Abstract

\textbf{Background:} HbA\textsubscript{1c} is considered as “gold standard” to evaluate glycemic control in patients with diabetes. Hemoglobin variants are mutant forms of hemoglobin that can occur by genetic changes in specific amino acid that can affect the accuracy of HbA\textsubscript{1c} measurements. High performance liquid chromatography (HPLC) is the standard method for HbA1c but inaccurate HbA1c values can occur when hemoglobin variants are present in diabetic patient. The aim of our study is to see Turbidimetric Inhibition Immunoassay (TINIA) method can report HbA1c values in diabetic patients with variant hemoglobin when the values are inaccurate on HPLC.

\textbf{Methods:} 7590 diabetic patients were analyzed for HbA1c by HPLC method from BIRDEM General Hospital during December 2013 to January 2014. HbA1c levels were again measured by TINIA method in 50 cases out of 7590 who showed either undetectable / below normal HbA1c levels. Hb electrophoresis confirmed the variant hemoglobin in few cases

\textbf{Results:} 50 cases out of 7590 (0.65\%) had either undetectable / below normal HbA\textsubscript{1c} levels by HPLC method. Males-26 and females-24; and the ratio was 0.92:1. In 27 cases, Hb\textsubscript{A} \textsubscript{1c} values were undetectable by HPLC method but in the reportable range by TINIA method. In the other 23 cases, Hb\textsubscript{A} \textsubscript{1c} levels were below the reportable range (<4\%) by HPLC method but were in the normal or higher range by TINIA method. On Bland Altman plot, TINIA method did not agree with HPLC method in variant cases.

\textbf{Conclusion:} In South East Asia where Hb variant is high, Low or undetectable HbA\textsubscript{1c} level by HPLC may be a convenient clue for screening of hemoglobinopathies especially among diabetic population in Bangladesh. All laboratories should have alternative method of HbA1c testing like TINIA along with HPLC for correct determination of glycemic control in variant cases

\textbf{Key words:} HbA \textsubscript{1c}, Hb variant, TINIA.

\textbf{(BIRDEM Med J 2018; 8(2): 114-117)}

Introduction

HbA\textsubscript{1c} is gold standard to evaluate the degree of glycemic control in diabetic patients.\textsuperscript{1,2} The American Diabetes Association recommended an HbA\textsubscript{1c} goal of less than 7\%, while the American Association of Clinical Endocrinology recommended less than 6.5\%.\textsuperscript{3,4} A value of less than 6\% indicates good glycemic control over last the three months, but more than 9\% indicates poor control.\textsuperscript{5}

Different assay methods are being used to measure the level of the HbA1c. These methods are based on different analytical principles such as immune turbidimetry, cation exchange chromatography , boronate affinity chromatography.\textsuperscript{6,7} However, presently, cation exchange performed by HPLC is the most widely used assay method.\textsuperscript{8}

Hemoglobin variants are mutant forms of hemoglobin caused by variations in genetics. They usually affect
the functionality and/or the stability of the hemoglobin molecule. Known variants in our region are Hb E, Hb F, Hb D-Punjab etc. Hemoglobinopathies create a major public health concern in south asia, with an estimated 17 million thalassemia carriers in India, 8 million carriers in Pakistan, 3 million in Bangladesh and 0.5 million in Sri Lanka.

Hemoglobinopathies create a major public health concern in south asia, with an estimated 17 million thalassemia carriers in India, 8 million carriers in Pakistan, 3 million in Bangladesh and 0.5 million in Sri Lanka.

Haemoglobin variants (e.g. Hbs trait, Hbc trait) and derivatives can affect the accuracy of HbA1c measurements. Glycated HbA1c may indicate the value of glycemic control for a diabetic patient for the last 120 days. Any condition that shortens erythrocyte survival e.g. recovery from acute blood loss, hemolytic anemia will falsely lower HbA1c test results regardless of the assay method used.

The purpose of this study is to see Turbidimetric Inhibition Immunoassay (TINIA) method can report HbA1c values in diabetic patients with variant hemoglobin when the values are inaccurate on High-performance liquid chromatography (HPLC).

Methods
This cross-sectional study was performed on stable adult type 2 diabetic patients attending BIRDEM General Hospital from December 2013 to January 2014 after taking ethical clearance. All EDTA blood samples were first analyzed for HbA1c by HPLC method using VARIANT-II TURBO- Bio Rad Laboratories (USA). Samples that showed undetectable or below 4% HbA1c levels by HPLC method as well as a variant window on the HPLC chromatogram were selected for comparison with TINIA method using Dade Behring autoanalyzer (USA). Patients with iron deficiency anemia, uremia or samples showing presence of carbamyl-Hb (cHb) by HPLC based HbA1C analysis were excluded. Samples were classified into Group I, consisted of samples that showed undetectable levels of HbA1c values by HPLC method and Group II, consisted of samples showing HbA1c values below the reportable range (<4%) by HPLC. Hemoglobin electrophoresis was performed by alkaline method on agarose gel on randomly selected 7 samples that showed undetectable or below 4% HbA1c levels by HPLC method as well as a variant window on the HPLC chromatogram.

Correlation coefficient and linear regression were used to determine whether the presence of hemoglobin variants caused a statistically significant difference (P < 0.05) in HbA1c results measured by HPLC as compared to Turbidimetric Inhibition Immunoassay using SPSS 11.5. Bland Altman Plot was derived using MedCalc Statistical software.

Results
Among the 7590 samples analyzed within the study period, 50 samples were initially found to show undetectable or below normal (<4%) HbA1c values by HPLC method. Among the 50 cases, there were 26 males and 24 females with a ratio of 0.92:1. Comparison of HPLC and TINIA method was performed on 50 subjects. 27 cases showed undetected level of HbA1c by HPLC (n = 27, Group I) and 23 cases showed below normal or less than 4% (n=23, Group II) HbA1c values and presence of variant window on HPLC chromatogram. On seven randomly selected cases, alkaline electrophoresis showed presence of HbE in all of the cases. When measured by TINIA method, all the cases in Group I that had undetectable levels of HbA1c produced reportable values (Figure 1). The mean HbA1c in TINIA method was 9.62% in Group I.

Figure 1. Values of HbA1c derived by HPLC and TINIA method (Group I). Values are undetectable by HPLC method but within the reportable range by TINIA method.

Group II (23 cases) with below normal (<4%) HbA1c by HPLC showed reportable values by TINIA method (Figure 2). The difference between the values reported by the two methods were statistically significant (p<0.0001). The mean HbA1c in HPLC was 3.17% and in TINIA method was 8.57%.
The test results of two methods were plotted on Bland Altman Plot and showed a poor bias of -5.4 (-10.4 to -0.4) in 95% confidence intervals (Figure 3) indicating no agreement between two methods. All the 50 cases showed variant window on HPLC. Hb electrophoresis showed Hb E trait in all the patients. In our study hemoglobin variants affect the results obtain by HPLC methods but not TINIA method. Bland Altman Plot was used to calculate the mean difference and agreement between two methodologies. The plot did not show good agreement between two methods in variant cases. The disagreement between HPLC method and TINIA in the presence of hemoglobinopathy was also observed by other researchers. A study also showed significantly lower HbA1c values measured by HPLC when compared to the immunoassay, in patients with heterozygous Hb E.

HbA1c is hemoglobin which is glycated at the N-terminal of the β chain [N-deoxyfructosylhemoglobin] and is denoted as the HbA0 peak. The area under the peak is proportional to the amount of analyte present. Hemoglobin having an ionic charge similar to either HbA0 or HbA1c will co-elute with the respective peak and interfere with the results. Inaccurate HbA1c values can occur when hemoglobin variants or its glycated derivatives cannot be separated from HbA0 or HbA1c. Co-elution of the hemoglobin variant with HbA1c will cause gross overestimation of HbA1c, while co-elution of the hemoglobin variant with HbA, with resolution of the glycated hemoglobin variant from HbA1c, will underestimate the HbA1c results. Similar results were found in our study.

Discussion
In this study, HbA1c results obtained by Cation Exchange HPLC method were compared with TINIA method. The aim of this study was to evaluate a method with a greater practicability and improved precision in case of diabetic patient with variant hemoglobin where accurate HbA1c measurements are a challenge. In this study, HPLC produced undetectable A1c in 27 cases and below normal results in 23 cases. All the 50 cases showed variant window on HPLC. Hb electrophoresis showed Hb E trait in all the patients. In our study hemoglobin variants affect the results obtain by HPLC methods but not TINIA method. Bland Altman Plot was used to calculate the mean difference and agreement between two methodologies. The plot did not show good agreement between two methods in variant cases. The disagreement between HPLC method and TINIA in the presence of hemoglobinopathy was also observed by other researchers. A study also showed significantly lower HbA1c values measured by HPLC when compared to the immunoassay, in patients with heterozygous Hb E.

HbA1c is hemoglobin which is glycated at the N-terminal of the β chain [N-deoxyfructosylhemoglobin] and is denoted as the HbA0 peak. The area under the peak is proportional to the amount of analyte present. Hemoglobin having an ionic charge similar to either HbA0 or HbA1c will co-elute with the respective peak and interfere with the results. Inaccurate HbA1c values can occur when hemoglobin variants or its glycated derivatives cannot be separated from HbA0 or HbA1c. Co-elution of the hemoglobin variant with HbA1c will cause gross overestimation of HbA1c, while co-elution of the hemoglobin variant with HbA, with resolution of the glycated hemoglobin variant from HbA1c, will underestimate the HbA1c results. Similar results were found in our study.

Immunoturbidimetric assays on the other hand, quantify HbA1c using antibody-mediated inhibition of latex agglutination. Monoclonal and poly-clonal antibodies (Abs) used in some of these methods recognize the N-terminal glycated amino acid in the context of the first 4 to 10 amino acids of the Hb β-chain. Any variant that does not result in changes in the first four to 10 N-terminal amino acids of the β-chain of Hb therefore do not affect the results by TINIA method. However, in contrast to ion-exchange chromatography and boronate-affinity methods, principle of immunoturbidimetric assays does not allow the user to recognize spurious alterations in Hb elution profiles or pat-terms. For these reasons, immunoturbidimetric method selection should be considered cautiously in populations where there is a high prevalence of Hb variants.
Limitation
In this study we did not do Hb electrophoresis in all patients, so further study should be done by incorporating Hb electrophoresis in all patients.

Conclusion
In Southeast Asia where populations have a high prevalence of hemoglobinopathies like HbE, methods for the determination of glycated Hb must be carefully selected to allow accurate determination of HbA1c. For the measurement of HbA1c level, all laboratories should offer alternative forms of testing, such as Turbidimetric Inhibition Immunoassay or affinity chromatography besides HPLC for correct determination of glycemic control in variant cases. Proper knowledge of hemoglobin variants affecting the measurements HbA1c level is essential, in order to avoid mismanagement of diabetic patients. Low or undetectable HbA1c level by HPLC may be a convenient clue for screening of hemoglobinopathies.

Conflict of interest: Nothing to declare.

References